Newswise — MIAMI (March 16, 2026) – Cancer treatment is often described as a race against time. But for many patients, chemotherapy-induced thrombocytopenia (CIT) creates a roadblock—forcing clinicians to delay or reduce treatment. A new phase 3 clinical trial published in The New England Journal of Medicine suggests there may now be a way to keep that journey moving forward.
In the international RECITE trial, investigators found that romiplostim, a thrombopoietin receptor agonist, significantly reduced chemotherapy dose delays and reductions in patients with gastrointestinal cancers who developed persistent low platelet counts during treatment. The findings mark a potential shift in how oncologists manage one of chemotherapy’s most stubborn complications—and how they preserve the intensity…